512 related articles for article (PubMed ID: 27248662)
1. Sub-acute systemic erythropoietin administration reduces ischemic brain injury in an age-dependent manner.
Thériault P; Le Béhot A; ElAli A; Rivest S
Oncotarget; 2016 Jun; 7(24):35552-35561. PubMed ID: 27248662
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effects of erythropoietin pretreatment in a rodent model of transient middle cerebral artery occlusion.
Ratilal BO; Arroja MM; Rocha JP; Fernandes AM; Barateiro AP; Brites DM; Pinto RM; Sepodes BM; Mota-Filipe HD
J Neurosurg; 2014 Jul; 121(1):55-62. PubMed ID: 24702327
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of CD147 (Cluster of Differentiation 147) Ameliorates Acute Ischemic Stroke in Mice by Reducing Thromboinflammation.
Jin R; Xiao AY; Chen R; Granger DN; Li G
Stroke; 2017 Dec; 48(12):3356-3365. PubMed ID: 29114092
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylated recombinant HSP27 protects the brain and attenuates blood-brain barrier disruption following stroke in mice receiving intravenous tissue-plasminogen activator.
Shimada Y; Shimura H; Tanaka R; Yamashiro K; Koike M; Uchiyama Y; Urabe T; Hattori N
PLoS One; 2018; 13(5):e0198039. PubMed ID: 29795667
[TBL] [Abstract][Full Text] [Related]
5. Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia.
Wang Y; Zhang ZG; Rhodes K; Renzi M; Zhang RL; Kapke A; Lu M; Pool C; Heavner G; Chopp M
Br J Pharmacol; 2007 Aug; 151(8):1377-84. PubMed ID: 17603558
[TBL] [Abstract][Full Text] [Related]
6. Combination of tissue-plasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice.
Zechariah A; ElAli A; Hermann DM
Stroke; 2010 May; 41(5):1008-12. PubMed ID: 20360548
[TBL] [Abstract][Full Text] [Related]
7. Canonical Wnt Pathway Maintains Blood-Brain Barrier Integrity upon Ischemic Stroke and Its Activation Ameliorates Tissue Plasminogen Activator Therapy.
Jean LeBlanc N; Menet R; Picard K; Parent G; Tremblay MÈ; ElAli A
Mol Neurobiol; 2019 Sep; 56(9):6521-6538. PubMed ID: 30852795
[TBL] [Abstract][Full Text] [Related]
8. The erythropoietin-derived peptide MK-X and erythropoietin have neuroprotective effects against ischemic brain damage.
Yoo SJ; Cho B; Lee D; Son G; Lee YB; Soo Han H; Kim E; Moon C; Moon C
Cell Death Dis; 2017 Aug; 8(8):e3003. PubMed ID: 28817120
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin reduces brain injury after intracerebral hemorrhagic stroke in rats.
Yu Z; Tang L; Chen L; Li J; Wu W; Hu C
Mol Med Rep; 2013 Nov; 8(5):1315-22. PubMed ID: 24008820
[TBL] [Abstract][Full Text] [Related]
10. Intra-artery infusion of recombinant human erythropoietin reduces blood-brain barrier disruption in rats following cerebral ischemia and reperfusion.
Wang R; Wu X; Liang J; Qi Z; Liu X; Min L; Ji X; Luo Y; Zhao H
Int J Neurosci; 2015; 125(9):693-702. PubMed ID: 25226558
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and safety of erythropoietin for neuroprotection after perinatal arterial ischemic stroke.
Benders MJ; van der Aa NE; Roks M; van Straaten HL; Isgum I; Viergever MA; Groenendaal F; de Vries LS; van Bel F
J Pediatr; 2014 Mar; 164(3):481-6.e1-2. PubMed ID: 24321539
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: a potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO).
Chen G; Shi JX; Hang CH; Xie W; Liu J; Liu X
Neurosci Lett; 2007 Oct; 425(3):177-82. PubMed ID: 17825990
[TBL] [Abstract][Full Text] [Related]
13. Pinocembrin Protects Blood-Brain Barrier Function and Expands the Therapeutic Time Window for Tissue-Type Plasminogen Activator Treatment in a Rat Thromboembolic Stroke Model.
Ma Y; Li L; Kong L; Zhu Z; Zhang W; Song J; Chang J; Du G
Biomed Res Int; 2018; 2018():8943210. PubMed ID: 29850586
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin in combination of tissue plasminogen activator exacerbates brain hemorrhage when treatment is initiated 6 hours after stroke.
Jia L; Chopp M; Zhang L; Lu M; Zhang Z
Stroke; 2010 Sep; 41(9):2071-6. PubMed ID: 20671252
[TBL] [Abstract][Full Text] [Related]
15. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia.
Yu YP; Xu QQ; Zhang Q; Zhang WP; Zhang LH; Wei EQ
Neurosci Lett; 2005 Oct; 387(1):5-10. PubMed ID: 16054296
[TBL] [Abstract][Full Text] [Related]
16. Recombinant tissue-type plasminogen activator transiently enhances blood-brain barrier permeability during cerebral ischemia through vascular endothelial growth factor-mediated endothelial endocytosis in mice.
Suzuki Y; Nagai N; Yamakawa K; Muranaka Y; Hokamura K; Umemura K
J Cereb Blood Flow Metab; 2015 Dec; 35(12):2021-31. PubMed ID: 26219596
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human erythropoietin in the treatment of acute ischemic stroke.
Ehrenreich H; Weissenborn K; Prange H; Schneider D; Weimar C; Wartenberg K; Schellinger PD; Bohn M; Becker H; Wegrzyn M; Jähnig P; Herrmann M; Knauth M; Bähr M; Heide W; Wagner A; Schwab S; Reichmann H; Schwendemann G; Dengler R; Kastrup A; Bartels C;
Stroke; 2009 Dec; 40(12):e647-56. PubMed ID: 19834012
[TBL] [Abstract][Full Text] [Related]
18. Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice.
Wang L; Fan W; Cai P; Fan M; Zhu X; Dai Y; Sun C; Cheng Y; Zheng P; Zhao BQ
Ann Neurol; 2013 Feb; 73(2):189-98. PubMed ID: 23280993
[TBL] [Abstract][Full Text] [Related]
19. The neuroprotective effect of erythropoietin-transduced human mesenchymal stromal cells in an animal model of ischemic stroke.
Cho GW; Koh SH; Kim MH; Yoo AR; Noh MY; Oh S; Kim SH
Brain Res; 2010 Sep; 1353():1-13. PubMed ID: 20547143
[TBL] [Abstract][Full Text] [Related]
20. Intracerebroventricular Delivery of Recombinant NAMPT Deters Inflammation and Protects Against Cerebral Ischemia.
Chen F; Weng Z; Xia Q; Cao C; Leak RK; Han L; Xiao J; Graham SH; Cao G
Transl Stroke Res; 2019 Dec; 10(6):719-728. PubMed ID: 30820847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
